To validate the potential of MRI to identify tumour-specific properties, the imaging technique is often used in combination with immunohistochemistry in view of correlating MRI-specific quantitative parameters and biomarkers that evaluate tumour cell growth and proliferation (Ki67), metastatic index (HER2), oestrogen receptor (ER), angiogenesis (CD31, VEGFR-2) [41] and also pimonidazole and CAIX staining for the assessment of hypoxia [42]. This evidence concerns the gene PECAM1 and neoplasm.